Skip to Main Content

We are a few days away from the start of the biggest and most important biotech business meeting of the year — the J.P. Morgan Healthcare Conference in San Francisco. If you sit through enough presentations at J.P. Morgan, you start to get buzz-phrase fatigue. Seemingly everything is a “transformational” “holy grail” of a “game-changer,” endorsed by “key opinion leaders” with “clinically meaningful” “optionality.”

But it doesn’t have to be that way.


Mike Huckman is a global practice leader at the PR firm W20, and he’s experienced J.P. Morgan from both sides of the podium, first as a biopharma reporter at CNBC and now in his career advising drug companies on how not to be boring.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!